Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Free Cash Flow (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Free Cash Flow for 4 consecutive years, with -$18.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 28.62% to -$18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.9 million through Dec 2025, up 27.04% year-over-year, with the annual reading at -$93.9 million for FY2025, 27.04% up from the prior year.
  • Free Cash Flow hit -$18.7 million in Q4 2025 for Axsome Therapeutics, down from $988000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $988000.0 in Q3 2025 to a low of -$55.5 million in Q2 2023.
  • Historically, Free Cash Flow has averaged -$30.3 million across 4 years, with a median of -$30.3 million in 2023.
  • Biggest five-year swings in Free Cash Flow: tumbled 809.11% in 2024 and later skyrocketed 105.28% in 2025.
  • Year by year, Free Cash Flow stood at -$27.7 million in 2022, then fell by 9.46% to -$30.4 million in 2023, then rose by 13.62% to -$26.2 million in 2024, then grew by 28.62% to -$18.7 million in 2025.
  • Business Quant data shows Free Cash Flow for AXSM at -$18.7 million in Q4 2025, $988000.0 in Q3 2025, and -$32.4 million in Q2 2025.